Prenetics' IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics

Prenetics’ IM8 entered a 10-year exclusive worldwide partnership with Authentic Brands Group to build Care Bears by IM8, a family health and wellness brand expected to launch gummy multivitamins for children and adults in 1H 2027. Prenetics will record all brand revenue and pay Authentic a royalty. The announcement cites a global gummy supplements market projected to nearly double to approximately US$47.8 billion by 2030.

Analysis

The deal adds a potentially valuable customer-acquisition asset, not yet an underwritable earnings stream. A familiar family brand could lower trust barriers and improve trial conversion versus a new supplement label; if buyers reorder, the licensing model may scale with less brand-building friction. But brand awareness does not establish supplement credibility, repeat purchase, or profitable customer acquisition. The economics hinge on royalty rate, product gross margin, paid-marketing burden, retailer access, and repeat rates—none are disclosed. Recording revenue at Prenetics also does not mean retaining the full revenue economics.

The 2030 category forecast is a broad market estimate, not evidence of Care Bears by IM8’s addressable share. Incumbents such as Olly, SmartyPants, and L’il Critters already compete for family supplement spend; a licensed character may differentiate packaging but is readily matched by promotion and distribution. Execution risks include product quality and substantiation, child-directed marketing scrutiny, and whether a 10-year exclusive commitment limits flexibility if the concept underperforms.

Near term, the announcement supports sentiment but provides no basis to revise earnings. Over 1–3 months, watch for launch timing, disclosed royalty/economic terms, retail commitments, and evidence of pre-launch demand. The 6–18 month test is repeat purchasing and contribution economics after marketing—not launch sell-in. A contrarian risk is that investors capitalize the category growth headline while overlooking royalty leakage and the long lag to revenue. No standalone trade is justified before unit economics are disclosed.

Key Decisions for Investors

• Treat PRE as a watch, not a buy-on-headline: seek the royalty rate, product-level gross margin, marketing/CAC budget, distribution commitments, and repeat-purchase data before underwriting earnings contribution.
• Use the next 1–3 months for catalyst monitoring: confirm whether the 1H 2027 launch schedule, product claims, and retail or direct-channel plans become more specific. Without those disclosures, assign the partnership option value rather than forecast revenue.
• If PRE rallies materially on the announcement alone, avoid chasing; the risk/reward is asymmetric to disappointment because no sales or profit targets were provided. Reassess only alongside disclosed economics or measurable demand indicators.
• Falsify the positive thesis if launch timing slips, distribution remains limited, customer acquisition depends on sustained heavy discounting, or repeat rates fail to support attractive contribution economics.